

REPÚBLICA DE COLOMBIA  
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Resolución N° 30735

Ref. Expediente N° NC2022/0004978

*Por la cual se otorga una Patente de Invención*

**LA SUPERINTENDENTE DE INDUSTRIA Y COMERCIO**

en ejercicio de sus facultades legales, en especial de las conferidas en el numeral 24 del artículo 3° del Decreto 4886 de 2011, y

**CONSIDERANDO:**

Que mediante escrito radicado en esta Superintendencia el 20 de abril de 2022 con el N° NC2022/0004978, por WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD., entró a fase nacional la solicitud de patente de invención titulada "INHIBIDOR DE IRAK Y MÉTODO DE PREPARACIÓN PARA EL MISMO Y USO DEL MISMO", que corresponde a la solicitud internacional PCT/CN2020/117093 del 23 de septiembre de 2020.

Que la solicitud fue publicada en la Gaceta de la Propiedad Industrial N° 960 el 29 de abril de 2022, sin que se hubieran presentado oposiciones por parte de terceros.

Que realizado el examen de fondo mediante Oficio No. 15089 de 27 de agosto de 2024, se requirió al solicitante en los términos del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina para que presentara respuesta a las observaciones de carácter técnico, relacionadas con la patentabilidad o cumplimiento de los requisitos establecidos por esta Decisión para la concesión de la patente.

Que el solicitante mediante escrito radicado bajo el N° NC2024/0015224 el 7 de noviembre de 2024, respondió oportunamente el requerimiento formulado y bajo el mismo radicado N° NC2024/0015224 el 7 de noviembre de 2024 presentó las reivindicaciones 1 a 15 que reemplazan las originalmente presentadas. Posteriormente, mediante escrito radicado bajo el N° NC2024/0015408 el 13 de noviembre de 2024, el solicitante presentó las reivindicaciones 1 a 15 para que sean tenidas en cuenta al momento de realizar el examen definitivo de la solicitud. Se acepta este último capítulo reivindicatorio presentado, comoquiera que se ajusta a las prescripciones contenidas en el artículo 34 de la Decisión 486.

Que en el presente caso de las reivindicaciones 1 a 15 incluidas en el radicado N° NC2024/0015408 el 13 de noviembre de 2024, superan las objeciones por Artículo 30 de la Decisión 486 por falta de claridad y sustento, las cuales fueron requeridas mediante Oficio No. 15089 de 27 de agosto de 2024, dado que se ha limitado a derivados de indazolcarboxamidas con una estructura química específica que incluye un N-óxido.

Que en virtud de lo dispuesto en el artículo 14 de la Decisión 486 expedida por la Comisión de la Comunidad Andina *"Los países miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial."*

Que en el presente caso las reivindicaciones 1 a 15, presentes en el radicado N° NC2024/0015408 el 13 de noviembre de 2024, cumple los requisitos indicados en el considerando anterior, toda vez que se refiere a derivados de indazolcarboxamidas como

Ref. Expediente N° NC2022/0004978

inhibidores de IRAK4, que difiere de la información del estado de la técnica más cercano WO2017148902, en que los derivados de indazolcarboxamidas presentan un grupo un N-óxido en el anillo A y los grupos R1, R2 y R3 están limitados a opciones específicas, como hidrocarbilos alifáticos (C1-C6), cicloalquilos (C3-C6), heterociclos y heteroarilos.

Adicionalmente, estas diferencias no se encuentran sugeridas en el estado de la técnica y como consecuencia de ello, se evidencia que derivados de indazolcarboxamidas con una estructura química específica que incluye un N-óxido en el anillo A y grupos R1, R2 y R3, presentan una mayor actividad inhibidora de IRAK4 entre 1.7 nM y 28.0 nM, y una mejor selectividad debido a la baja inhibición del canal hERG útiles para el tratamiento de enfermedades, tanto autoinmunes como inflamatorias (por ejemplo, 5.09% para el Compuesto 001) en comparación con el compuesto A (Descripción, Tablas 1 a 3 páginas 72 a 75).

En consecuencia, las reivindicaciones 1 a 15 cumplen los requisitos de novedad, nivel inventivo y aplicación industrial establecidos en la normatividad citada en precedencia y esta

Que de acuerdo con la modificación presentada por el solicitante en el escrito radicado bajo el N° NC2024/0006262 del 16 de mayo de 2024 y teniendo en cuenta el objeto de la solicitud, esta oficina acepta el siguiente título: “DERIVADOS DE INDAZOLCARBOXAMIDAS, ÚTILES PARA LA INHIBICIÓN DE IRAK”.

Con fundamento en las anteriores consideraciones, la Superintendente de Industria y Comercio,

## RESUELVE

**ARTÍCULO 1:** Otorgar patente de invención a la solicitud que entró en fase nacional en virtud del Tratado de Cooperación en Materia de Patentes (PCT), para la creación titulada:

**“DERIVADOS DE INDAZOLCARBOXAMIDAS, ÚTILES PARA LA INHIBICIÓN DE IRAK”**

**Clasificación IPC:** C07D 401/12, C07D 401/14, C07D 413/14, A61K 31/4439, A61P 35/00, A61P 19/06, A61P 19/02, A61P 17/06, A61P 3/00, A61P 9/10, A61P 31/04, A61P 29/00, A61P 11/06, A61P 37/08.

**Reivindicaciones:** 1 a 15 incluidas en el radicado bajo el No NC2024/0015408 el 13 de noviembre de 2024, de acuerdo con el Anexo No. 1.

**Titular:** WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD.

**Dirección:** BIOLAKE C2-2, No. 666 HIGH-TECH ROAD, EAST LAKE HIGH-TECH DEVELOPMENT ZONE, WUHAN 430075 HUBEI, CHINA.

**Inventores:** Guozhong YE, Chenli DING, Yawen DING, Qian HE y Chaodong WANG.

**Prioridad N°** 24/09/2019, CN (CHINA), 201910906833.7.

**Solicitud internacional N°:** PCT/CN2020/117093 **Fecha:** 23 de septiembre de 2020.

Ref. Expediente N° NC2022/0004978

**Vigente desde:** 23 de septiembre de 2020

**Hasta:** 23 de septiembre de 2040.

**ARTÍCULO 2:** El titular tendrá los derechos y las obligaciones establecidos en la Decisión 486 de la Comisión de la Comunidad Andina y en las demás disposiciones legales vigentes sobre propiedad industrial, precisando que para mantener vigente la patente se deberá cancelar la tasa anual de mantenimiento, conforme lo dispone el artículo 80 de la referida norma comunitaria.

**ARTÍCULO 3:** Notificar el contenido de la presente resolución a WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. advirtiéndole que contra ella procede el recurso de reposición, ante la Superintendente de Industria y Comercio, el cual podrá ser interpuesto en el momento de la notificación o dentro de los diez (10) días hábiles siguientes a ella.

### NOTIFÍQUESE Y CÚMPLASE

Dada en Bogotá D.C., el 22 de mayo de 2025

LA SUPERINTENDENTE DE INDUSTRIA Y COMERCIO,




Firmado digitalmente  
por: CIELO ELAINNE  
RUSINQUE URREGO  
Fecha: 2025.05.22  
12:02:44 COT  
Razón: Validez jurídica.  
Ubicación: Bogotá,  
Colombia.

Ref. Expediente N° NC2022/0004978

**ANEXO No. 1**

**REIVINDICACIONES CONCEDIDAS**

1. Un compuesto de fórmula I, o un estereoisómero, un racemato, un tautómero o una sal farmacéuticamente aceptable del mismo,



Fórmula I

en donde,

el anillo A es un heteroarilo de 5 a 10 miembros que contienen uno de N;

cada  $R_1$  se selecciona independientemente de los siguientes grupos opcionalmente sustituidos con uno, dos, o tres R: hidrocarbilo alifático ( $C_1-C_6$ ), cicloalquilo  $C_{3-6}$ ;

cada  $R_2$  es seleccionado independientemente de los siguientes grupos opcionalmente sustituidos con uno, dos, o tres R: hidrocarbilo alifático ( $C_1-C_6$ ), cicloalquilo  $C_{3-6}$ , heterociclilo de 3-12 miembros que tiene 1 heteroátomo seleccionado de N, o heteroarilo de 5-10 miembros que tiene 1-2 heteroátomos seleccionados entre N y O, y  $-NR_aR_b$ ;

cada  $R_3$  es seleccionado independientemente entre hidrógeno, halógeno y los siguientes grupos opcionalmente sustituidos con uno, dos, o tres R: hidrocarbilo alifático ( $C_1-C_6$ ), hidrocarbilo alifático ( $C_1-C_6$ ) que comprende opcionalmente un heteroátomo seleccionado entre O,  $C_{3-6}$  cicloalquilo y  $-NR_aR_b$ ;

W se selecciona entre O o es un enlace sencillo;

$R_a$  y  $R_b$  se selecciona independientemente entre H e hidrocarbilo alifático ( $C_1-C_6$ );

cada R se selecciona independientemente entre halógeno, CN, OH,  $NR_aR_b$  y los siguientes grupos opcionalmente sustituidos con uno, dos, o más R': hidrocarbilo alifático ( $C_1-C_6$ ), cicloalquilo  $C_{3-6}$ ;

cada R' se selecciona independientemente entre halógeno CN, OH y  $NR_aR_b$ ; y

Ref. Expediente N° NC2022/0004978

n es 1; y m es 1.

2. El compuesto según la reivindicación 1 en el que el hidrocarbilo alifático ( $C_1-C_6$ ) opcionalmente comprende un heteroátomo seleccionado de O se selecciona de hidrocarbiloaloxi alifático ( $C_1-C_6$ ), hidrocarbiloaloxi alifático ( $C_1-C_3$ ); hidrocarbilo alifático ( $C_1-C_3$ );

el anillo A es piridina;

cada hidrocarbilo alifático ( $C_1-C_6$ ) es independientemente seleccionado entre alquilo ( $C_1-C_6$ ), alquenilo ( $C_2-C_6$ ) y alquinilo ( $C_2-C_6$ );


cada halógeno es independientemente seleccionado entre F, Cl, Br e I; y

cada cicloalquilo  $C_{3-6}$  es independientemente seleccionado entre ciclopropilo, ciclobutilo, ciclopentilo y ciclohexilo.

3. El compuesto según la reivindicación 1, en el que el hidrocarbilo alifático ( $C_1-C_6$ ) se selecciona de ( $C_1-C_6$ ) alquilo, ( $C_2-C_6$ ) alquenilo y ( $C_2-C_6$ ) alquinilo.

4. El compuesto según la reivindicación 1, en el que:



$R_1$  se selecciona de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: metilo, etilo, *n*-propilo, isopropilo, *n*-butilo, isobutilo, *terc*-butilo, *n*-pentilo, isopentilo, neopentilo, *n*-hexilo, etenilo, 1-propenilo, 2-propenilo, 1-metiletlenilo, 1-butenilo, 1-etiletlenilo, 1-metil-2-propenilo, 2-butenilo, 3-butenilo, 2-metil-1-propenilo, 2-metil-2-propenilo, 1-pentenilo, 1-hexenilo, etinilo, 1-propinilo, 2-propinilo, 1-butinilo, 1-metil-2-propinilo, 3-butinilo, 1-pentinilo, 1-hexinilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo,




$R_2$  se selecciona de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: metilo, etilo, *n*-propilo, isopropilo, *n*-butilo, isobutilo, *terc*-butilo, *n*-pentilo, isopentilo, neopentilo, *n*-hexilo, etenilo, 1-propenilo, 2-propenilo, 1-metiletlenilo, 1-butenilo, 1-

Ref. Expediente N° NC2022/0004978

etilenilo, 1-metil-2-propenilo, 2-butenilo, 3-butenilo, 2-metil-1-propenilo, 2-metil-2-propenilo, 1-pentenilo, 1-hexenilo, etinilo, 1-propinilo, 2-propinilo, 1-butenilo, 1-metil-2-propinilo, 3-butenilo, 1-pentinilo, 1-hexinilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, *N*-metilaminometilo, *N*-metilaminoetilo, *N*-etilaminoetilo, *N*, *N*-dimetilaminometilo, *N*, *N*-dimetilaminoetilo, *N*, *N*-dietilaminoetilo, amino, *N*, *N*-dimetilamino, *N*, *N*-dietilamino, tetrahidropirrolilo, piperidinilo, piridilo, pirazinilo, pirrolilo, imidazolilo,

pirazolilo, oxazolilo, isoxazolilo, , y ; y,


R<sub>3</sub> es seleccionados de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: metilo, etilo, *n*-propilo, isopropilo, *n*-butilo, isobutilo, *terc*-butilo, *n*-pentilo, isopentilo, neopentilo, *n*-hexilo, etenilo, 1-propenilo, 2-propenilo, 1-metilenilo, 1-butenilo, 1-etilenilo, 1-metil-2-propenilo, 2-butenilo, 3-butenilo, 2-metil-1-propenilo, 2-metil-2-propenilo, 1-pentenilo, 1-hexenilo, etinilo, 1-propinilo, 2-propinilo, 1-butenilo, 1-metil-2-propinilo, 3-butenilo, 1-pentinilo, 1-hexinilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, metoxi, etoxilo, propoxi, butoxi, pentiloxi, metoximetilo, etoximetilo, propoximetilo, metoxietilo, etoxietilo, propoxietilo, metoxipropilo, etoxilpropilo, propoxipropilo, *N*-metilaminometilo, *N*-metilaminoetilo, *N*-etilaminoetilo, *N*, *N*-dimetilaminometilo, *N*, *N*-dimetilaminoetilo, *N*, *N*-dietilaminoetilo, amino, *N*, *N*-dimetilamino, *N*, *N*-dietilamino,




"" indica el sitio de conexión del grupo.

5. El compuesto según la reivindicación 1 o 2, en el que:

R<sub>1</sub> se selecciona de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: ciclopentilo, ciclohexilo,




Ref. Expediente N° NC2022/0004978




"~" indica el sitio de conexión del grupo.

6. El compuesto según cualquiera de las reivindicaciones 1 a 5, en el que R<sub>1</sub> es



7. El compuesto según la reivindicación 1 ó 2, en el que:


R<sub>2</sub> se selecciona de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: metilo, etilo, ciclopropilo, N, N - dimetilamino, tetrahidropirrolilo, piridilo, pirazolilo, oxazolilo,



y "~" indica el sitio de conexión del grupo.

8. El compuesto según la reivindicación 1 ó 2, en el que:

R<sub>3</sub> se selecciona de los siguientes grupos opcionalmente sustituidos con uno, dos o tres R: metilo, isopropilo, ciclopropilo, metoxi, amino, N, N-dimetilamino,




"~" indica el sitio de conexión del grupo.


Ref. Expediente N° NC2022/0004978

9. El compuesto según cualquiera de las reivindicaciones 1 a 8, en el que  $R_2$  y  $R_3$  son cada uno independientemente metilo o etilo, opcionalmente sustituido con uno, dos o tres R.


10. El compuesto según cualquiera de las reivindicaciones 1 a 9, que es un compuesto de fórmula Ia, fórmula Ib, fórmula Ic, fórmula Id y fórmula Ie:




fórmula Ia




fórmula Ib



fórmula Ic



fórmula Id




fórmula Ie

o un estereoisómero, un racemato, un tautómero o una sal farmacéuticamente aceptable del mismo.

11. Compuesto según la reivindicación 10, que es un compuesto de fórmula Ie:


Ref. Expediente N° NC2022/0004978




fórmula le

o un estereoisómero, un racemato o una sal farmacéuticamente aceptable del mismo.


12. Un compuesto seleccionado de las siguientes estructuras:




001




002




003




004




005



006

















007

















008















Ref. Expediente N° NC2022/0004978



Ref. Expediente N° NC2022/0004978

















Ref. Expediente N° NC2022/0004978

































Ref. Expediente N° NC2022/0004978

















Ref. Expediente N° NC2022/0004978















Ref. Expediente N° NC2022/0004978



Ref. Expediente N° NC2022/0004978

















Ref. Expediente N° NC2022/0004978

































Ref. Expediente N° NC2022/0004978













Ref. Expediente N° NC2022/0004978




Ref. Expediente N° NC2022/0004978




Ref. Expediente N° NC2022/0004978




Ref. Expediente N° NC2022/0004978




171




172




173




174




175




176




177




178




179



180

















181

















182



Ref. Expediente N° NC2022/0004978

















Ref. Expediente N° NC2022/0004978



















Ref. Expediente N° NC2022/0004978


















Ref. Expediente N° NC2022/0004978




Ref. Expediente N° NC2022/0004978




Ref. Expediente N° NC2022/0004978




251




252




253




254




255




256




257




258




259



260




261




262


Ref. Expediente N° NC2022/0004978




263




264




265




266




267




268




269



270




271




272


Ref. Expediente N° NC2022/0004978




273




274




275




276




277




278




279



280




281




282


Ref. Expediente N° NC2022/0004978




283




284




285




286




287



288




289



290

o un estereoisómero, un racemato, un tautómero o una sal farmacéuticamente aceptable del mismo.

13. Un compuesto que es:




001

o un estereoisómero, un racemato o una sal farmacéuticamente aceptable del mismo.

Ref. Expediente N° NC2022/0004978

14. El compuesto según la reivindicación 13, que es:



15. Una composición farmacéutica que comprende el compuesto según cualquiera de las reivindicaciones 1-14.